Purpose Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role in the development of both hepatocellular carcinoma and B-cell non-Hodgkin´s lymphoma (B-NHL). The biologic mechanisms underlying the lymphomagenic activity of the virus so far are under investigation. In this study, the role of antiviral (anti-HCV) treatment in B-NHL associated with HCV infection is evaluated. Patients and Methods Thirteen patients with histologically proven low-grade B-NHL characterized by an indolent course (ie, doubling time no less than 1 year, no bulky disease) and carrying HCV infection were enrolled on the study. All patients underwent antiviral treatment alone with pegilated interferon and ribavirin. Response assessment took place at 6 and 12 months. Results Of the twelve assessable patients, seven (58%) achieved complete response and two (16%) partial hematologic response at 14.1 +/- 9.7 months (range, 2 to 24 months, median follow-up, 14 months), while two had stable disease with only one patient experiencing progression of disease. Hematologic responses (complete and partial, 75%) were highly significantly associated to clearance or decrease in serum HCV viral load following treatment (P = .005). Virologic response was more likely to be seen in HCV genotype 2 (P = 035), while hematologic response did not correlate with the viral genotype. Treatment-related toxicity did not cause discontinuation of therapy in all but two patients, one of whom, however, achieved complete response. Conclusion This experience strongly provides a role for antiviral treatment in patients affected by HCV-related, low-grade, B-cell NHL.
|Data di pubblicazione:||2005|
|Titolo:||Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience|
|Autore/i:||D. Vallisa; P. Bernuzzi; L. Arcaini; S. Sacchi; V. Callea; R. Marasca; A. Lazzaro; E. Trabacchi; E. Anselmi; A.L. Arcari; C. Moroni; R. Berte; M. Lazzarino; L. Cavanna.|
|Codice identificativo ISI:||WOS:000226591000011|
|Codice identificativo Scopus:||2-s2.0-20044377730|
|Citazione:||Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience / D. Vallisa; P. Bernuzzi; L. Arcaini; S. Sacchi; V. Callea; R. Marasca; A. Lazzaro; E. Trabacchi; E. Anselmi; A.L. Arcari; C. Moroni; R. Berte; M. Lazzarino; L. Cavanna.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 23(3)(2005), pp. 468-473.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
|Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin’s Lymphoma A Multicenter Italian Experience.pdf||Post-print||Administrator Richiedi una copia|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris